Novel encapsulation technology for oral delivery
Freund Pharmatec
AGC is to open an API and intermediate production plant in Japan to meet increased demand from the aging population.
Japan-based AGC is investing JPY3.7bn ($48m) in the 28,400 sq m manufacturing site to ramp up its active pharmaceutical ingredient (API) and intermediate business. The facility is due to open in a year and help sales at the business unit hit JPY15bn by 2014.
AGC is using its chemical technology to provide fluorinated compounds and is now adding a fourth API and intermediate plant to meet the expected growth in demand.
